Persistent low body weight in humans is associated with higher mitochondrial activity in white adipose tissue.


Journal

The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027

Informations de publication

Date de publication:
01 09 2019
Historique:
received: 22 01 2019
accepted: 19 06 2019
pubmed: 3 8 2019
medline: 25 3 2020
entrez: 3 8 2019
Statut: ppublish

Résumé

Constitutional thinness (CT) is a state of low but stable body weight (BMI ≤18 kg/m2). CT subjects have normal-range hormonal profiles and food intake but exhibit resistance to weight gain despite living in the modern world's obesogenic environment. The goal of this study is to identify molecular mechanisms underlying this protective phenotype against weight gain. We conducted a clinical overfeeding study on 30 CT subjects and 30 controls (BMI 20-25 kg/m2) matched for age and sex. We performed clinical and integrative molecular and transcriptomic analyses on white adipose and muscle tissues. Our results demonstrate that adipocytes were markedly smaller in CT individuals (mean ± SEM: 2174 ± 142 μm 2) compared with controls (3586 ± 216 μm2) (P < 0.01). The mitochondrial respiratory capacity was higher in CT adipose tissue, particularly at the level of complex II of the electron transport chain (2.2-fold increase; P < 0.01). This higher activity was paralleled by an increase in mitochondrial number (CT compared with control: 784 ± 27 compared with 675 ± 30 mitochondrial DNA molecules per cell; P < 0.05). No evidence for uncoupled respiration or "browning" of the white adipose tissue was found. In accordance with the mitochondrial differences, CT subjects had a distinct adipose transcriptomic profile [62 differentially expressed genes (false discovery rate of 0.1 and log fold change >0.75)], with many differentially expressed genes associating with positive metabolic outcomes. Pathway analyses revealed an increase in fatty acid oxidation ( P = 3 × 10-04) but also triglyceride biosynthesis (P = 3.6 × 10-04). No differential response to the overfeeding was observed in the 2 groups. The distinct molecular signature of the adipose tissue in CT individuals suggests the presence of augm ented futile lipid cycling, rather than mitochondrial uncoupling, as a way to increase energy expenditure in CT individuals. We propose that increased mitochondrial function in adipose tissue is an important mediator in sustaining the low body weight in CT individuals. This knowledge could ultimately allow more targeted approaches for weight management treatment strategies. This trial was registered at clinicaltrials.gov as NCT02004821.

Sections du résumé

BACKGROUND
Constitutional thinness (CT) is a state of low but stable body weight (BMI ≤18 kg/m2). CT subjects have normal-range hormonal profiles and food intake but exhibit resistance to weight gain despite living in the modern world's obesogenic environment.
OBJECTIVE
The goal of this study is to identify molecular mechanisms underlying this protective phenotype against weight gain.
METHODS
We conducted a clinical overfeeding study on 30 CT subjects and 30 controls (BMI 20-25 kg/m2) matched for age and sex. We performed clinical and integrative molecular and transcriptomic analyses on white adipose and muscle tissues.
RESULTS
Our results demonstrate that adipocytes were markedly smaller in CT individuals (mean ± SEM: 2174 ± 142 μm 2) compared with controls (3586 ± 216 μm2) (P < 0.01). The mitochondrial respiratory capacity was higher in CT adipose tissue, particularly at the level of complex II of the electron transport chain (2.2-fold increase; P < 0.01). This higher activity was paralleled by an increase in mitochondrial number (CT compared with control: 784 ± 27 compared with 675 ± 30 mitochondrial DNA molecules per cell; P < 0.05). No evidence for uncoupled respiration or "browning" of the white adipose tissue was found. In accordance with the mitochondrial differences, CT subjects had a distinct adipose transcriptomic profile [62 differentially expressed genes (false discovery rate of 0.1 and log fold change >0.75)], with many differentially expressed genes associating with positive metabolic outcomes. Pathway analyses revealed an increase in fatty acid oxidation ( P = 3 × 10-04) but also triglyceride biosynthesis (P = 3.6 × 10-04). No differential response to the overfeeding was observed in the 2 groups.
CONCLUSIONS
The distinct molecular signature of the adipose tissue in CT individuals suggests the presence of augm ented futile lipid cycling, rather than mitochondrial uncoupling, as a way to increase energy expenditure in CT individuals. We propose that increased mitochondrial function in adipose tissue is an important mediator in sustaining the low body weight in CT individuals. This knowledge could ultimately allow more targeted approaches for weight management treatment strategies. This trial was registered at clinicaltrials.gov as NCT02004821.

Identifiants

pubmed: 31374571
pii: S0002-9165(22)01225-4
doi: 10.1093/ajcn/nqz144
pmc: PMC6736451
doi:

Banques de données

ClinicalTrials.gov
['NCT02004821']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

605-616

Informations de copyright

Copyright © American Society for Nutrition 2019.

Références

Am J Clin Nutr. 2000 Sep;72(3):694-701
pubmed: 10966886
Obes Res. 2004 Feb;12(2):233-40
pubmed: 14981215
Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E132-7
pubmed: 16912058
Am J Clin Nutr. 2007 Apr;85(4):967-71
pubmed: 17413094
Eur J Clin Nutr. 2008 Jun;62(6):704-11
pubmed: 17440515
Brain. 2007 Jul;130(Pt 7):1808-18
pubmed: 17535833
J Clin Endocrinol Metab. 2008 Jan;93(1):110-7
pubmed: 17956951
Cell. 2008 Jan 25;132(2):171-6
pubmed: 18243090
Int J Obes (Lond). 2008 Dec;32 Suppl 7:S109-19
pubmed: 19136979
Am J Physiol Endocrinol Metab. 2010 Jan;298(1):E108-16
pubmed: 19887594
Am J Clin Nutr. 2011 May;93(5):963-7
pubmed: 21367952
Biomarkers. 2011 May;16(3):243-51
pubmed: 21506696
Nature. 2011 Sep 25;478(7367):110-3
pubmed: 21947005
J Clin Endocrinol Metab. 2012 Feb;97(2):E183-92
pubmed: 22162470
Obesity (Silver Spring). 2012 Aug;20(8):1585-90
pubmed: 22240727
J Lipid Res. 2012 Dec;53(12):2791-6
pubmed: 22993232
Obes Rev. 2012 Dec;13 Suppl 2:97-104
pubmed: 23107263
Obes Rev. 2012 Dec;13 Suppl 2:105-21
pubmed: 23107264
J Occup Environ Hyg. 2013;10(2):78-85
pubmed: 23259751
J Clin Endocrinol Metab. 2013 Mar;98(3):1214-8
pubmed: 23393181
Biochim Biophys Acta. 2013 May;1831(5):986-1003
pubmed: 23454373
Cell. 2014 Jan 16;156(1-2):20-44
pubmed: 24439368
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Nutr Diabetes. 2014 Jul 14;4:e126
pubmed: 25027794
Exp Physiol. 2014 Sep;99(9):1168-78
pubmed: 25128326
Curr Protoc Mouse Biol. 2015 Jun 01;5(2):135-153
pubmed: 26069081
Cell. 2015 Sep 24;163(1):84-94
pubmed: 26406372
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6579-88
pubmed: 26554015
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Ann Endocrinol (Paris). 2016 Oct;77(5):563-569
pubmed: 27424229
BMC Genomics. 2017 Apr 26;18(1):326
pubmed: 28441938
Front Endocrinol (Lausanne). 2017 Jun 13;8:130
pubmed: 28659868
Methods Mol Biol. 2017;1619:433-449
pubmed: 28674902
Psychoneuroendocrinology. 2017 Oct;84:94-100
pubmed: 28692876
Am J Clin Nutr. 2017 Sep;106(3):736-746
pubmed: 28793995
J Proteome Res. 2018 Apr 6;17(4):1426-1435
pubmed: 29451788
Acta Physiol (Oxf). 2018 Nov;224(3):e13097
pubmed: 29754437
Cell Metab. 2018 Jul 03;28(1):45-54.e3
pubmed: 29861390
Environ Health Perspect. 1979 Dec;33:101-6
pubmed: 540610
Crit Rev Clin Lab Sci. 1980;12(3):241-77
pubmed: 6998654
Rev Prat. 1982 Jan 11;32(3):245-7
pubmed: 7071484
Aviat Space Environ Med. 1999 Jan;70(1):42-50
pubmed: 9895020

Auteurs

Yiin Ling (Y)

Division of Endocrinology, Diabetes, Metabolism, and Eating Disorders, CHU St-Etienne, France.
Eating Disorders, Addictions, and Extreme Bodyweight Research Group (TAPE) EA 7423, Jean Monnet University, St-Etienne, France.

Jérôme Carayol (J)

Metabolic Health, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Bogdan Galusca (B)

Division of Endocrinology, Diabetes, Metabolism, and Eating Disorders, CHU St-Etienne, France.
Eating Disorders, Addictions, and Extreme Bodyweight Research Group (TAPE) EA 7423, Jean Monnet University, St-Etienne, France.

Carles Canto (C)

Metabolic Health, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Christophe Montaurier (C)

Clermont Auvergne University, INRA, Human Nutrition Unit, CHU Clermont-Ferrand, Service de Nutrition Clinique, CRNH Auvergne, Clermont-Ferrand, France.

Alice Matone (A)

The Microsoft Research, University of Trento Centre for Computational Systems Biology (COSBI), Rovereto, Italy.

Irene Vassallo (I)

Precision Medicine Group, Quartz Bio SA, Geneva, Switzerland.

Kaori Minehira (K)

Metabolic Health, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Virginie Alexandre (V)

Metabolic Health, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Ornella Cominetti (O)

Proteomics, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Antonio Núñez Galindo (A)

Proteomics, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

John Corthésy (J)

Proteomics, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Loïc Dayon (L)

Proteomics, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Aline Charpagne (A)

Genomics, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Sylviane Métairon (S)

Genomics, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Frédéric Raymond (F)

Genomics, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Patrick Descombes (P)

Genomics, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

François Casteillo (F)

Pathology Department, CHU St-Etienne, France.

Michel Peoc'h (M)

Pathology Department, CHU St-Etienne, France.

Radu Palaghiu (R)

Surgery Department, CHU St-Etienne, France.

Léonard Féasson (L)

Interuniversity Laboratory of Motricity and Biology (LIBM) EA 7424, Jean Monnet University, St-Etienne, France.

Yves Boirie (Y)

Clermont Auvergne University, INRA, Human Nutrition Unit, CHU Clermont-Ferrand, Service de Nutrition Clinique, CRNH Auvergne, Clermont-Ferrand, France.

Bruno Estour (B)

Division of Endocrinology, Diabetes, Metabolism, and Eating Disorders, CHU St-Etienne, France.
Eating Disorders, Addictions, and Extreme Bodyweight Research Group (TAPE) EA 7423, Jean Monnet University, St-Etienne, France.

Jörg Hager (J)

Metabolic Health, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Natacha Germain (N)

Division of Endocrinology, Diabetes, Metabolism, and Eating Disorders, CHU St-Etienne, France.
Eating Disorders, Addictions, and Extreme Bodyweight Research Group (TAPE) EA 7423, Jean Monnet University, St-Etienne, France.

Nele Gheldof (N)

Metabolic Health, Nestlé Research, EPFL Innovation Park, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH